Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. - Wikidata - wikimedia - TriplyDB

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

http://www.wikidata.org/entity/Q34106830

about

Acute myeloid leukemia in the older adults Update on rational targeted therapy in AML Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies An update of current treatments for adult acute myeloid leukemia Development of cell-cycle checkpoint therapy for solid tumors Volasertib for AML: clinical use and patient consideration Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders Polo-like kinase and its inhibitors: Ready for the match to start?Future prospects of therapeutic clinical trials in acute myeloid leukemia.A phase I study of volasertib combined with afatinib, in advanced solid tumors.Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.Emerging therapies for acute myeloid leukemia.Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.Molecular therapy for acute myeloid leukaemia.Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma.Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy.Cell cycle proteins as promising targets in cancer therapy Novel drugs for older patients with acute myeloid leukemia.Targeted therapy of acute myeloid leukemia.Targeting polo-like kinase 1 in acute myeloid leukemia.The role of Plk3 in oncogenesis.Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Emerging therapeutic drugs for AML.Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo The artful management of older patients with acute myeloid leukemia.Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells.

P2860

Q26740584-101B25A9-CBF3-4A62-91DD-35355D2EEA73 Q26766152-11F2457D-4556-4A2D-930D-98B4AD983567 Q26772235-1FDADBD0-4220-482C-AED5-A01B3C8E6651 Q26776396-3A879A3A-F53C-410A-A98D-77EE02F5F73A Q26781187-F2271B35-F97F-45EF-B553-E9500AC00360 Q26801131-DE97780E-ED98-4744-AE89-2C0033E753FC Q26991736-106376B1-8EE2-4443-A133-9C88AF72E5A4 Q28073970-1BA1D61D-DA45-454E-A138-A4AE0B6F738B Q28087433-25447C31-F03C-4F74-83BA-9C47D62F16C0 Q30244168-B331BA11-03BF-4826-BBA3-569122CD2465 Q33425698-B2FD81BA-B4A9-4EF0-8988-8A034665BA11 Q33428061-36AB8C80-D6D9-4813-AEBA-6369730CFC4A Q33443830-EDE905FE-8646-4294-B77D-B1F79435A632 Q33576363-5811AB97-FE0B-42AD-87F0-84B29F8F2CB4 Q33873351-52E9DD01-09BA-4E0B-9E53-BE84AAAF4B66 Q33925672-BF539EDE-102D-4E8F-AB8A-0D6413D80CD1 Q35581741-09A4370F-C8A7-40C5-AF8A-4551F0A7F154 Q35801683-C607C55E-BDD1-40AB-B7FF-277B448E724B Q36053792-EF8D1F31-4D35-45FA-93DB-3E3FED0586F8 Q36157664-D19FFD87-AE3A-4A67-9697-B1798207342B Q36207913-71B42EBA-9140-49F7-8418-04022FCA3B01 Q36386336-3A3385B1-E2A7-476F-A979-F483FD372BB2 Q36452688-EABF9904-2983-446F-BA3E-437590B39627 Q36467485-0E61624B-60BA-4E9F-A4E5-2CADDEF739C5 Q36516564-7C5503FD-110D-4755-AB8E-A3188D413444 Q37447866-47746BEB-393F-4308-B822-3CD7682E633B Q37619757-D161A967-540D-49A7-853F-0F45A9B8E4CD Q37693690-4DEC0F0B-A170-4ACC-8249-F5E98C55350C Q38241761-2DF5B725-03F8-4560-9724-1B040A2DEDFF Q38333251-63BBF028-FEF5-4782-A7A1-CED5FFB7D78B Q38398864-D31BAA2E-F173-49F0-90BA-F27C41508CE7 Q38444150-7BC37CF9-D01C-4EB6-8993-34A19E108A84 Q38601723-72D1C978-D8DB-4BC0-ABA7-BFCD3DC14AD4 Q38642017-2552755B-2B26-4CF0-A47A-4979748224A8 Q38644941-F150D3D1-93B3-41D5-9A09-BF33E6F78C28 Q38664735-86F30BF3-0EFF-4BC6-8EF1-DD125A913F49 Q38667491-06BFF2A6-D841-40F1-8896-49B3E090ADFF Q38707201-4A2724E4-BDAF-4B74-A993-0BE34B1158EB Q38734206-F5EFC4CB-37EB-457C-A439-EA5A147EDD74 Q38742560-1A8D5B03-AFB0-4403-A7B0-8835B5E75AFD

P2860

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

http://www.wikidata.org/entity/Q34106830

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Randomized, phase 2 trial of l ...... uitable for induction therapy.

@ast

Randomized, phase 2 trial of l ...... uitable for induction therapy.

@en

Randomized, phase 2 trial of l ...... uitable for induction therapy.

@nl

type

label

Randomized, phase 2 trial of l ...... uitable for induction therapy.

@ast

Randomized, phase 2 trial of l ...... uitable for induction therapy.

@en

Randomized, phase 2 trial of l ...... uitable for induction therapy.

@nl

prefLabel

Randomized, phase 2 trial of l ...... uitable for induction therapy.

@ast

Randomized, phase 2 trial of l ...... uitable for induction therapy.

@en

Randomized, phase 2 trial of l ...... uitable for induction therapy.

@nl

P1433

Q34106830-CDFB434E-4ECE-48C9-ADA7-46A27817567E

P1476

Q34106830-2DA33F85-A565-4BB9-AB6D-4AFA1C8A20F2

P2093

Q34106830-3948A96D-1F96-4073-9042-042EC76D9C3C

Q34106830-4B0D53FB-8CCB-4EF8-8301-55A7BF023931

Q34106830-4B3C30DB-9E32-4735-838F-38B0E173287F

Q34106830-60B7AD19-1545-4A7B-93AD-B48F08A6AF34

Q34106830-60DCAFAD-5E61-49E5-8559-6BE7272608D8

Q34106830-69B0A086-6E84-490E-8D0E-ADFE84CD43BC

Q34106830-6DBD4369-0A5E-4E4B-AB83-73ADC31E379C

Q34106830-863E8DCE-9657-446A-AE97-4CD696BFFDDD

Q34106830-9CD0F455-E787-4653-8071-2F0AA0E25E8D

Q34106830-A968F974-36B9-4111-8430-30E8CB297613

P2860

Q34106830-078A903C-73F8-4DEB-94AC-7AF027A28461

Q34106830-08941E3C-CD77-4537-BC6F-04FA14A19299

Q34106830-18234C58-F39A-4F47-AB09-AD0EAD338A81

Q34106830-1871702C-428F-46B9-A875-ED7944392706

Q34106830-277DCCB0-04CF-476C-9EA3-630ED50F4629

Q34106830-3D4A7945-B3F1-40B8-9319-EC0B49F41D31

Q34106830-44742850-B584-429A-8776-A41CE8C29A66

Q34106830-49BE7EBF-AA09-4D5B-8BB4-06376EF094A7

Q34106830-4C053550-EA16-43EF-92C8-71A5968F9DCF

Q34106830-4E5398CA-C80C-4602-8D3B-5B826ABDDF94

P304

Q34106830-76D09376-9FDC-448D-BFDA-4EE949B6F772

P31

Q34106830-A80D08CE-5A9D-4FC3-83BA-A4BD55E6A91E

P356

Q34106830-9A860B39-8685-4467-A566-C861E3371C04

P407

Q34106830-F43E9D82-8A93-4796-A54C-70F87A0DDD45

P433

Q34106830-F67900D1-FBB4-4D11-BE27-5A2B460858DA

P478

Q34106830-D78DB6A3-8786-44B8-B0CD-E689136D9705

P50

Q34106830-50531EC2-A497-4DFE-84FD-A99058A7A66C

Q34106830-67D08770-9042-4BC6-86B6-41B1EFC2CC1A

Q34106830-F14B0551-47C8-4C7D-9F72-9143530499E5

P577

Q34106830-457A5778-CC2F-471A-ACCB-D327A707E409

P5875

Q34106830-8602A774-C8D3-40F6-BAFB-AF2F9F627FD5

P698

Q34106830-59F37DC3-7B9E-4A03-9561-729A4622DA43

P921

Q34106830-5AE69E12-40DC-4F58-88AC-A5337CB5B42C

P932

Q34106830-71A04BFF-37F4-4E87-A505-ED9EB8870E2E

P356

BLOOD-2014-03-560557

P1433

P1476

Randomized, phase 2 trial of l ...... uitable for induction therapy.

@en

P2093

Alf Haaland

http://www.w3.org/2001/XMLSchema#string

Alwin Krämer

http://www.w3.org/2001/XMLSchema#string

Emmanuel Raffoux

http://www.w3.org/2001/XMLSchema#string

Florian Voss

http://www.w3.org/2001/XMLSchema#string

Holger Fritsch

http://www.w3.org/2001/XMLSchema#string

Johan Maertens

http://www.w3.org/2001/XMLSchema#string

Joseph M Brandwein

http://www.w3.org/2001/XMLSchema#string

Loic Fouillard

http://www.w3.org/2001/XMLSchema#string

Michael Lübbert

http://www.w3.org/2001/XMLSchema#string

Oliver G Ottmann

http://www.w3.org/2001/XMLSchema#string

P2860

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Normal cells, but not cancer cells, survive severe Plk1 depletion.

Age and acute myeloid leukemia.

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

A review of methods for futility stopping based on conditional power.

P304

1426-1433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-03-560557

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Carsten Müller-Tidow

Hartmut Döhner

Konstanze Döhner

P577

2014-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263779336

http://www.w3.org/2001/XMLSchema#string

P698

25006120

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4148765

http://www.w3.org/2001/XMLSchema#string